Healthcare
Seer, Inc.(SEER)
Live Price
Offline$1.74
+1.16% today
1Y Change
-9.14%
Window
Jun 23, 2025 โ Jun 5, 2026
- Market Cap
- $110.00M
- Revenue Growth
- +18.9%
- EPS Growth
- +7.9%
- Dividend Yield
- 0.0%
Coverage: 240 bars ยท Jun 23, 2025 โ Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Seer, Inc. (SEER) is a Healthcare stock with a market cap of $110.00M and listed on NASDAQ. The stock last traded around $1.74 and down 9.1% across the available one-year price window (Jun 23, 2025 โ Jun 5, 2026). Baseline metrics include revenue growth of +18.9%, EPS growth of +7.9%, a dividend yield of 0.0%. What stands out right now is revenue +18.9%, EPS +7.9%, free cash flow +6.9% with operating margin -470.5% and ROIC -27.6%. Valuation sits in the middle of the pack at price/sales 6.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SEER price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+18.9% vs +7.6% peer median
Operating Margin
Below sector median
-470.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +18.9% and EPS at +7.9%, with operating margin around -470.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.3% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -2.7% | -7.7% | โ |
2026 Feb 26, 2026 | +9.4% | -17.3% | -11.5% | -18.8% |
2025 Nov 6, 2025 | +0.0% | -3.2% | -5.6% | -13.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SEER
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SEER Max Drawdown
-29.96%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SEER and SPY.
Company Overview
Seer, Inc.
NASDAQ Global Select
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
- Leadership
- Omid C. Farokhzad
- IPO Date
- Dec 4, 2020
- Employees
- 134
- Street Address
- 3800 Bridge Parkway
- Mailing
- Redwood City, CA, 94065
- Region
- Redwood City, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 453 0000
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 6.9
- Price/Book
- 0.4
Growth
- Revenue
- +18.9%
- EPS
- +7.9%
- Free Cash Flow
- +6.9%
Profitability
- Gross Margin
- 51.1%
- Operating Margin
- -470.5%
- Net Margin
- -444.0%
- ROE
- -26.0%
- ROIC
- -27.6%
Balance Sheet
- Debt/Equity
- 0.09
- Current Ratio
- 12.84
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.